Table 2.
Percentage Change in Markers of Inflammation, Cellular Adhesion, Coagulation, and Low-Density Lipoprotein (LDL) Cholesterol, by Study Group
| Marker | Statin, Percentage Change (n = 72a) | Placebo, Percentage Change (n = 75a) | P |
|---|---|---|---|
| hsCRP level | −12.5 (−54.6 to 22.2) | 0.0 (−42.4 to 54.7) | .14 |
| IL-6 level | −24.2 (−42.4 to 29.4) | −2.1 (−39.5 to 32.9) | .24 |
| sTNFR-I level | −7.1 (−41.7 to 6.3)b | −13.5 (−38.3 to 7.2)b | .77 |
| sTNFR-II level | 5.6 (−23.3 to 78.7)b | 22.5 (−9.9 to 63.4)b | .27 |
| sVCAM-1 level | 3.8 (−11.5 to 15.3) | 1.9 (−7.4 to 11.4) | .72 |
| sICAM-1 level | 6.2 (−8.2 to 19.0)b | 4.6 (8.1–20.7) | .56 |
| IP-10 level | −22 (−34.3 to −4.2)b | −12.1 (34.7–4.0) | .34 |
| D-dimer level | 6.9 (43.8 to −35.0) | 21.9 (−9.1 to 73.3)b | .23 |
| Fibrinogen level | 0.2 (−20.1 to 22.2) | 9.8 (−6.4 to 23.5)b | .16 |
| Lp-PLA2 level | −9.9 (−20.1 to −1.0)b | −1.9 (−8.6 to 13.3) | <.01 |
| LDL cholesterol level | −28 (−43 to −16)b | 3.8 (−0.7% to 17.2)b | <.01 |
Abbreviations: hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; IP-10, interferon γ–inducible protein 10; Lp-PLA2, lipoprotein-associated phospholipase A2; sTNFR-I, soluble tumor necrosis factor receptor I; sTNFR-II, soluble tumor necrosis factor receptor II; sICAM-1, soluble intercellular adhesion molecule I; sVCAM-1, soluble vascular cellular adhesion molecule I.
a Baseline numbers. At 24 weeks, 5 subjects in the statin group and 6 in the placebo group had withdrawn or were lost to follow-up.
b P < .05 for within-group changes.